February 27, 2014
1 min read

Positive preliminary results reported in phase 1b re-treatment trial of QLT091001

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Clinically meaningful improvements in visual fields and visual acuity have been reported in preliminary results from a phase 1b clinical trial of repeated treatments of oral QLT091001 in subjects with Leber congenital amaurosis or retinitis pigmentosa, according to a press release from QLT.

Specifically, the international multicenter trial targeted Leber congenital amaurosis or retinitis pigmentosa due to inherited genetic mutations in retinal pigment epithelium (RPE65) or lecithin:retinol acyltransferase (LRAT), the release said. The extension study included patients who been treated with a single course of QLT091001 in a previous phase 1b study.

To date, 19 of 27 subjects (70%) had an increase in visual fields in the retinal area from baseline of 20% or more, while 70% of subjects had an increase in visual acuity from baseline of five letters or more. The improvements were seen in at least one eye at two consecutive visits within 6 months from the start of any QLT091001 treatment course, according to the release.

Dosing in the study is completed, and follow-up is continuing. Final clinical data, including duration of response and other evaluations, are expected to be released in the third quarter.